Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Younes, A. (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood.
Chicago-стиль цитированияChen, Robert, et al. "Five-year Survival and Durability Results of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma." Blood 2016.
MLA-цитированиеChen, Robert, et al. "Five-year Survival and Durability Results of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma." Blood 2016.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.